Traws Pharma, Inc.
No SEC Form 4 filings for $TRAW in the last 30 days.
See all $TRAW insider activity →Traws Pharma, Inc. (TRAW) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2623190d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights · Advancing tivoxavir marboxil toward MHRA resubmission in Q3 2026 with a revised toxicology package, supporting initiation of the Phase 2a h
Traws Pharma, Inc. (TRAW) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001130598 0001130598 2026-07-08 2026-07-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report
Traws Pharma (TRAW) has announced a 15-day delay in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company attributes this delay to recurring operating losses, ongoing efforts to secure financing to meet Nasdaq listing requirements, and the need for KPMG LLP to complete audit procedures following management's going-concern assessment. Despite the delay, Traws Pharma provided preliminary financial results for 2025, projecting $2.8 million in revenue and a net income of approximately $9.2 million.
Over the past 7 days, alphai's AI scored 1 news story mentioning TRAW (Traws Pharma, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent TRAW coverage spans earnings, corporate actions and financial news.
Near-term catalyst is regulatory progress on the MHRA resubmission and potential resolution of the FDA clinical hold, alongside milestone-linked financing optionality.
The 8-K discloses equity-plan share authorization and related governance outcomes, which can affect dilution expectations and near-term sentiment.
The delay and financial uncertainties suggest potential short-term negative sentiment and increased volatility for TRAW shares.
alphai scores every news story that mentions TRAW with an AI model for sentiment and relevance, and aggregates insider trades from Traws Pharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Traws Pharma, Inc. (TRAW) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2623190d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights · Advancing tivoxavir marboxil toward MHRA resubmission in Q3 2026 with a revised toxicology package, supporting initiation of the Phase 2a h
6 min readTraws Pharma, Inc. (TRAW) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001130598 0001130598 2026-07-08 2026-07-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report
4 min readTraws Pharma (TRAW) has announced a 15-day delay in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company attributes this delay to recurring operating losses, ongoing efforts to secure financing to meet Nasdaq listing requirements, and the need for KPMG LLP to complete audit procedures following management's going-concern assessment. Despite the delay, Traws Pharma provided preliminary financial results for 2025, projecting $2.8 million in revenue and a net income of approximately $9.2 million.
3 min read